longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

NEPG

000597

4.620.00% ( 0.00 )
Delay Closed: Sep 16, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

NEPG (000597)

Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmace...

Open
4.61
High
4.65
Low
4.57
Prev. Close
4.62
Volume
72.75K
Turnover
33.57M
Avg Price
4.61
Bid/Ask Ratio
--
Amplitude
1.73%
52wk High
5.88
Volume Ratio
0.38
Turnover Ratio
0.51%
52wk Low
4.09
Float Mkt Cap
6.58B
Market CapCNY
6.59B
P/ETTM
30.70
P/EDynamic
39.30
P/EStatic
--
EPSTTM
0.151
EPSDynamic
0.118
EPSStatic
--
BVPS
3.88
P/B
1.19
Circulating Supply
1.42B
Dividend YieldTTM
1.19%
DividendTTM
0.06
Shares
1.43B
Min lot size
100
Currency
CNY

News

  • Zhitong · Oct 27, 2025 at 10:42 AM

    NEPG: The net profit for the third quarter was 43.5245 million yuan, a decrease of 14.92%

  • Zhitong · Oct 8, 2025 at 08:34 AM

    NEPG: The holding subsidiary has obtained approval for drug clinical trials

  • Zhitong · Sep 1, 2025 at 12:21 PM

    NEPG: Chief Financial Officer Zhou Yana resigns due to health reasons

  • Zhitong · Aug 26, 2025 at 12:34 PM

    NEPG: Net profit of 129 million yuan in the first half of 2025, a year-on-year decrease of 17.62%

  • Zhitong · Jun 13, 2025 at 12:04 AM

    China Galaxy Securities: Cell gene therapy has entered the stage of result realization, and CXO is expected to benefit first

  • Zhitong · Jun 4, 2025 at 12:42 PM

    NEPG: The active pharmaceutical ingredient fosfomycin trometamol has received CEP certification